RICHLAND, Wash., Jan. 13, 2016 /PRNewswire/ -- IsoRay Inc. (NYSE
MKT:ISR), a medical technology company and innovator in seed
brachytherapy and medical radioisotope applications for the
treatment of prostate, brain, lung, head and neck and gynecological
cancers, today announced a peer-reviewed publication of the results
of a retrospective study on the cost effectiveness of Cesuim-131 in
combination with surgical resection for metastatic brain tumors.
While parts of the manuscript were presented at a meeting of the
Society for Neuro-Oncology in 2012 in Washington, DC, the research paper - Wernicke,
A. Gabriella, et al., "The cost-effectiveness of surgical resection
and cesium-131 intraoperative brachytherapy versus surgical
resection and stereotactic radiosurgery in the treatment of
metastatic brain tumors." DOI 10.1007/s11060-015-2026-4 - was
published online on January 2, 2016,
in the Journal of Neuro-Oncology.
The patients in the study were treated at New York
Presbyterian/Weill Cornell Medical Center between 2008 and
2012. The treatment records as well as hospital and
outpatient charts of 49 patients with brain metastases were
retrospectively reviewed. These 49 patients were placed into
two groups. Twenty-four patients underwent treatment
with surgical resection (S) and Cesium-131 (Cs-131) intraoperative
brachytherapy, or S + Cs-131, and 25 patients underwent surgical
resection (S) and stereotactic radiosurgery (SRS), or S +
SRS. Hospital charges, survival, quality adjusted life years
(QALY) and incremental cost-effectiveness ratios (ICER) were
compared for the two groups.
The study concluded that surgical resection plus Cesium-131 (S +
Cs-131) is a more cost effective alternative to surgical resection
and stereotactic radiosurgery (S + SRS), with direct hospital costs
of treatment of $19,271 for S +
Cs-131 and $44,219 for S + SRS.
Median survival was greater for S + Cs-131 and resulted in a
greater quality adjusted life years (QALY). Relative to S + Cs-131,
S + SRS resulted in a negative incremental cost-effectiveness ratio
(ICER) as it was more expensive yet provided a lower QALY.
Therefore, from a resource allocation perspective, this study
concluded that S + Cs-131 for brain metastases is the more
cost-effective treatment option while providing a better quality of
life.
Bill Cavanagh, IsoRay interim
CEO, stated: "This study suggests that surgical resection with
intraoperative Cs-131 has proven cost-effectiveness for the
treatment of metastatic brain tumors while providing a better
quality of life. As the healthcare industry continues to
study the effective allocation of health resources, studies such as
this one are critical to providing cutting edge treatments in a
truly cost-effective manner. Interestingly, the measure used
in the study for quality of life was better as well."
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is
the sole producer of Cesium-131 brachytherapy seeds, which are
expanding brachytherapy options throughout the body. Learn more
about this innovative Richland,
Washington, company and explore the many benefits and uses
of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on
Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future
expectations, including: the advantages of our products and their
delivery systems, whether interest in and use of our products will
increase or continue, whether awareness and adoption of our
products in the medical community will continue or increase,
whether peer-reviewed publications of treatment results using our
products will report favorable results, whether S + Cs-131 will
demonstrate cost-effectiveness in the treatment of brain
metastases, and all other statements in this release, other than
historical facts, are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995
("PSLRA"). This statement is included for the express purpose of
availing IsoRay, Inc. of the protections of the safe harbor
provisions of the PSLRA. It is important to note that actual
results and ultimate corporate actions could differ materially from
those in such forward-looking statements based on such factors as
physician acceptance, training and use of our products, our ability
to successfully manufacture, market and sell our products, our
ability to manufacture our products in sufficient quantities to
meet demand within required delivery time periods while meeting our
quality control standards, our ability to enforce our intellectual
property rights, whether additional studies are released and
support the conclusions of past studies, whether ongoing patient
results with our products are favorable and in line with the
conclusions of clinical studies and initial patient results,
patient results achieved when our products are used for the
treatment of cancers and malignant diseases, successful completion
of future research and development activities, whether we, our
distributors and our customers will successfully obtain and
maintain all required regulatory approvals and licenses to market,
sell and use our products in its various forms, continued
compliance with ISO standards as audited by BSI, the success of our
sales and marketing efforts, changes in reimbursement rates,
changes in laws and regulations applicable to our products, and
other risks detailed from time to time in IsoRay's reports filed
with the SEC. Unless required to do so by law, the Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/clinical-study-discusses-cost-effectiveness-of-surgical-resection-and-isorays-cesium-131-intraoperative-brachytherapy-300203199.html
SOURCE IsoRay Inc.